TOKYO, May 12 (Pulse News Wire) – Shionogi & CO.,LTD. (4507.T) reported record revenue and profits for the fiscal year ended March 31, 2026.
Revenue reached ¥5,000 billion, up 614 million yen from the previous year, while operating profit increased by ¥101 million to ¥1,780 billion. Net profit attributable to owners of the parent rose to ¥2,060 billion, marking an 84% increase compared to the previous year. Key drivers included strong performance in domestic pharmaceutical products, particularly growth in respiratory infection medications and contributions from acquired entities such as Birdy Pharmaceutical. Additionally, robust sales of HIV franchises bolstered overall results.
Research and development expenses also saw a significant rise due to investments in new product lines and ongoing clinical trials. Looking ahead, Shionogi forecasts continued growth, aiming for five consecutive years of record-breaking revenues and four consecutive years of record operating profits. The company plans to enhance shareholder returns through consistent dividend increases and strategic share repurchases. For the fiscal year ending March 31, 2027, Shionogi expects to maintain its commitment to increasing annual dividends for the 15th consecutive year.
🟡 Confidence: Standard AI-translated content.